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Errata 
Page 108: Figure 2 should appear with the right side up. 
Page 180, left column, line 10 should read: 
similar conditions. A spcctral width of ± 2000 Hz and 2048 data points 
Page 180, left column, line 35 should read: 
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Page 197: Photograph was printed inverted. 
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Decision Making in Interstitial Stern Cells of Hydra 
T H O M A S C G . B O S C H and C H A R L E S N . D A V I D 
1 Z o o l o g i c a l I n s t i t u t e , University of M u n i c h , Luisenstr. 14, 8 0 0 0 M u n i c h 2 , F . R . G . 
Abstact. Intersitial stem cells in Hydra are a continuously 
proliferating and differentiating cell population. They repre-
sent a useful model System for studying mechanisms Control-
ling stem cell differentiation. H e r e we review our c u r r e n t 
knowledge ofthe differentiation potential of these cells, Inters-
titial stem cells are multipotent and able to differentiate into 
several different cell types. The differentiation decisions appear 
to be controlled by positional Signals and by the composition 
of the cellular environment. Since interstitial stem cells can be 
cultured in an in vivo environment and appear to be accessible 
to experimental m a n i p u l a t i o n by a ränge of new molecular 
techniques, an in vivo analysis of the molecular mechanisms 
underlying stem cell decision m a k i n g can now be approached. 
Introduction 
The freshwater polyp Hydra is a phylogenetically ancient 
multicellular organism with a relatively simple tissue struc-
ture. During asexual growth of the polyp its nerve cells, gland 
cells and nematocytes arise from a population of interstitial 
stem cells. Since these stem cells are a continuously prolifer-
ating and differentiating cell population which can be cul-
tured and analyzed in an in vivo environment, they represent 
a useful model System for analysing the mechanisms Controll-
ing stem cell differentiation. In this review we discuss the 
differentiation behavior of these cells and the factors in-
fluencing it. We demonstrate that the interstitial stem cells 
are multipotent in the sense that they are able to differentiate 
into somatic cells (nematocytes, nerve cells and gland cells) as 
well as into germ line cells (sperm and eggs). The differentia-
tion decisions appear to be controlled by morphogenetic 
Signals associated with the position of stem cells within the 
Correspondence to: Dr. Thomas C G . Bosch, University of 
Munich, Zoological Institute, Luisenstrasse 14, 8000 Munich 2, 
FRG 
Key Words: Hydra, interstital stem cells, differentiation, mor-
phogenetic Signals. 
body column as well as by the composition of the cellular 
environment and the presence of neuropeptides. We con-
clude by showing that hydra stem cells appear to be accessible 
to experimental manipulation by a ränge of new molecular 
techniques so that now an in vivo analysis of the molecular 
mechanisms underlying stem cell decision making can be 
approached. 
In vivo cloning of interstitial stem cells in hydra 
The main evidence for interstitial stem cells in H y d r a comes 
from in vivo cloning experiments (1, 2). To prepare intersti-
tial stem cell clones, small numbers of dissociated donor cells 
were mixed with large numbers of host cells and centrifuged 
to form aggregates which then regenerated normal polyps. In 
such regenerated polyps of Hydra magnipapillata all stem cell 
clones were capable of differentiating somatic cells, i.e. nerve 
cells, nematocytes and gland cells (2). Since 87 out of 92 
clones could also give rise to male and female gametes, we 
concluded that H. magnipapillata contains multipotent stem 
cells capable of germ line and somatic differentiation. Re-
cently, evidence for such a multipotent stem cell population 
has also been found in a second species of hydra, H . oligactis 
(3). 
In numerous cloning experiments no stem cell clones were 
found containing only one differentiated type of somatic 
cells. Thus, there is no evidence for extensively proliferating 
subpopulations of somatic intermediates (e.g., nerve precur-
sors) in hydra. This is supported by the Observation that in 
tissue which displays extensive nerve cell differentiation (the 
peduncle region of H . oligactis polyps) only stem cells and 
postmitotic nerve cell precursors are present (4). Thus, 
signals inducing nerve cell differentiation appear to affect the 
multipotent stem cells themselves. 
In the gamete differentiation pathway, however, unipotent 
subpopulations of interstitial cells have been isolated. They 
are capable of extensive proliferation but commited to either 
spermatogenesis (5) or oogenesis (3). These unipotent stem 
cells are present in asexually proliferating polyps in low 
numbers and dividing at a slower rate than their multipotent 
0258-851X/91 $2.00+.40 515 
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Figurc 1. Schematic diagram of the i n t e r s t i t i a l stem cells generating somatic and germ cells (modified f r o m Bosch and David, J 9 8 6 ) . 
precusor cells (6). In response to environmental Stimuli such 
as low temperature, these cells Start to proliferate rapidly and 
differentiate into gametes. Whether the environmental Stimu-
lus serves directly as a signal triggering these cells to gamete 
differentiation or whether the cells are able to complete their 
differentiation program only under certain environmental 
conditions remains to be shown. 
When cloning stem cells from male polyps of H. magnipa-
pillata we found, to our surprise, clones producing both male 
gametes and clones producing female gametes (2). Clones 
from female polyps, by comparison, differentiated female 
gametes only. The Observation of male and female gametes in 
male polyps raised the possibility that male stem cells could 
switch their sexual phenotype to female. To test this idea we 
recloned the stem cells from a male clone (7). After about 200 
days in culture we found 5 out of 15 male polyps containing 
both male and female stem cells. Thus, stem cells from male 
polyps indeed occasionally switch the sexual phenotype. Stem 
cells from female polyps, by comparison, were found to be 
stable in their sexual differentiation capacity after recloning. 
Two more features of hydra interstital stem cells are of 
interest. First, the interstitial stem cells are not only the 
precursors for germ cells but also themselves responsible for 
sex determination (8, 9). Somatic components (e.g., epithe-
lial cells) do not play a role in determining the sexual 
phenotype. Second, male interstitial cells of hydra suppress 
the ability of female stem cells to differentiate eggs thereby 
causing «masculinization» of females. They, however, do not 
interfere with the ability of female stem cells to proliferate 
and produce somatic cells. The suppression of female gamete 
differentiation by male interstitial cells was demonstrated 
experimentally by introducing male stem cells into female 
tissue by grafting (10, 11). The observed inhibition of female 
differentiation by male cells also explains the failure of 
female stem cells in «male» polyps to differentiate. The 
molecular nature of this suppression is completely unknown. 
Since a few male interstitial cells are sufficient to masculinize 
female tissue (10), direct cell-cell interaction between male 
and female cells probably is not involved. It appears more 
likely that male stem cells produce a humoral suppressor 
moleeule. Its molecular characterization promises interesting 
insights into how different cell populations communicate with 
each other in these ancient metazoa. Figure 1 summarizes 
these findings and illustrates our current view of the dif-
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Figurc 2. In vivo localization of i n t e r s t i t i a l stem cells of H y d r a m a g n i p a p i l l a t a in e p i t h e l i a l host tissue. The i n t e r s t i t i a l cells were introduced by I m p l a n t a t i o n 
of a small piece (about 3 0 0 e p i t h e l i a l cells) of donor tissue into e p i t h e l i a l host tissue. In this nerve free environment stem cells do not p r o l i f e r a t e but 
differentiate into nerve cells and nematocytes ( 1 9 ) . (A) C a m e r a l u c i d a d r a w i n g showing localization of donor tissue ( b l a c k ) , presence of donor i n t e r s t i t i a l 
cells 4 8 h r after I m p l a n t a t i o n (grey) and a r e a depicted in B ( s q u a r e ) . (B) V i s u a l i z a t i o n of donor i n t e r s t i t i a l cells by monoclonal antibody C 4 1 . 
ferentiation and proliferation potential of hydra interstitial 
stem cells. 
In vivo localization of interstitial stem cells 
Interstitial stem cells in hydra are located primarily in the 
ectoderm throughout the gastric region (12). Althougb 
there have been numerous reports of interstitial cell 
migration in hydra (13, 14, 15), recent experiments with 
genetically marked interstitial cell clones indicated that 
stem cells grow as contiguous patches of cells (16). The 
finding of patches of clonally derived interstitial cells 
implys that the extent of migration of interstitial stem cells 
i n vivo is limited. The earlier Observation of migration in 
transplantation experiments could be explained by the 
finding that wounding, i.e. grafting itself, stimulates 
migration (17). In undisturbed tissue, however, interstitial 
stem cells appear not to crawl around extensively. 
The growth of interstitial cells in clonal patches has 
important consequences for the distribution of stem cells 
to daughter polyps. For example, if in a male polyp (which 
contains male and female stem cells, see above) a clonal 
patch of female stem cells occurs close to the budding 
region, this bud will obtain only female cells and therefore 
become phenotypically female. Thus, due to the growth of 
stem cells in clonal patches male polyps can occasionally 
give rise to female polyps, as is indeed observed ex-
perimentally (ref. in 7). 
Role of the cellular environment in stem cell differentiation 
Interstitial cells grow and differentiate in the interstices 
between ectodermal epithelial cells. In addition to epithelial 
cells, the interstitial space can have contact to the mesoglea, a 
thin acellular basement membrane which is separating en-
doderm from ectoderm. Thus, the major cellular components 
of the microenvironment in which interstitial stem cells grow 
and make their decisions are epithelial cells and cells of the 
interstitial cell lineage themselves, i.e. nerve cells and nema-
toblasts. The mesoglea may represent an important acellular 
component of the microenvironment. To study the role of the 
cellular environment in stem cell proliferation and dif-
ferentiation, stem cells have been introduced into a variety of 
different host tissues by transplantation as illustrated in 
Figure 2. The results of a number of experiments have 
documented two environmental parameters as particularly 
important. The first parameter - nerve cell density in host 
tissue - positively influences proliferation. The second para-
meter - interstitial cell density - negatively influences prolif-
eration. 
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Nerve cells present in the head were shown to stimulate 
stem cell proliferation (18). When stem cells were introduced 
into host tissue with progressively increased numbers of nerve 
cells the growth rate of interstitial cells was positively corre-
lated to the nerve cell density (19). Hosts with low nerve cell 
density inhibit stem cell proliferation; hosts with normal high 
nerve cell densities support rapid stem cell proliferation. 
The growth rate of stem cells is also negatively correlated 
to the level of interstitial cells present: growth of interstitial 
cells is faster in tissue with reduced interstitial cell numbers 
than in normal tissue (6, 20, 21, 22). This finding indicates 
that stem cell proliferation is controlled by a feed back signal 
from interstitial cells and their derivatives: decreasing the 
number of stem cells causes an increase in the self-renewal 
probability (Ps) and leads to recovery of normal stem cell 
levels (22). Conversely, increasing the number of stem cells 
decreases the self-renewal probability. 
The nature of the signal(s) by which interstitial cells 
measure their density is unknown. There is evidence suggest-
ing that the feedback signal is of short ränge (19, 22, 23). 
When tissue containing a low density of stem cells is grafted 
to tissue with high interstitial cell density, the stem cells at 
low density continue to proliferate rapidly and are not 
affected by the stem cells growing at high density. Whether 
the signal is a diffusible molecule produced by stem cells or 
whether density measurement is mediated directly by cell-cell 
contact has not yet been determined. Feedback regulation by 
stem cell density does not, however, occur after grafting 
tissue between genetically unrelated strains (24). Under these 
conditions the stem cells behave as if the genetically distinct 
cells are not present. 
Factors influencing stem cell differentiation in vivo 
The differentiation pattern of interstitial stem cells exhibits a 
strong dependence on position along the body axis. Intersti-
tial stem cells are found throughout the gastric region; they 
are absent, however, in the head and foot region (12). 
Nematocyte differentiation occurs exclusively in the gastric 
region with stenoteles produced more proximally and de-
smonemes produced more distally (25). Thus, positional 
signals are involved in the decision for nerve and nematocyte 
differentiation. What molecules in the environment serve 
interstitial cells as positional cues in their decision making? 
Much attention has concentrated on the role of the 
neuropeptide «head activator» (HA) in specifying positional 
information in hydra (27). The 11 amino acid peptide (Glu-
Pro-Pro-Gly-Gly-Ser-Lys-Val-Ile-Leu-Phe; purified by Schal-
ler and Bodenmüller, (28) is capable of causing nerve cell 
commitment in all parts of hydra tissue (29) in the concentra-
tion ränge of 0.1 - 10 pM. Up to 50% of stem cells 
differentiate to nerve cells under such conditions compared to 
10% in control tissue (29). H A was found to stimulate nerve 
commitment if present during S phase (29, 30) implying that 
responses in target cells depend on their position in the cell 
cycle. After commitment nerve precursors are arrested in G2 
and require a second signal to differentiate into mature 
neurons. This differentiation inducing signal can be released 
by wounding (31) and can be replaced by H A (32). 
Do other neuropeptides in hydra also affect stem cell 
decisions? Neuropeptides with the carboxyterminus Arg-Phe-
N H 2 (RFamide) are ubiquitous in coelenterates (for review 
see 33). Antisera raised against RFamide stain a population 
of immunoreactive sensory neurons around the mouth of 
hydra and a Cluster of neurons in the peduncle (34). In 
ultrastructural studies RFamide like peptides were localized 
in dense-cored vesicles (35). They are thought to be released 
by exocytosis and act as hormones or neurotransmitters. In 
the marine hydrozoan Hydractinia the presence of RFamide + 
neurons is correlated with the capacity to metamorphose (36) 
implying that RFamide may serve as a signal molecule during 
development. In an attempt to examine these neuropeptides 
for their influence on interstitial cell differentiation, we have 
analyzed on hydra the effect of Pol-RFaminde I, a 7 amino 
acid peptide (Glu-Leu-Leu-Gly-Gly-Arg-Phe-NH2) isolated 
from Polyorchis medusae (37). Treatment of Hydra magnipa-
p i l l a t a polyps with 10"12 M Pol-RFamide caused a twofold 
increase in the nerve cell density in isolated gastric tissue 
(Bosch, unpublished Observation). Thus, at least two 
neuropeptides (head activator and Pol-RFamide) have been 
shown to affect interstitial stem cell behavior. Whether these 
neuropeptides directly affect stem cells or function indirectly, 
e.g., by stimulating the release of other biologically active 
peptide factors, remains to be shown. 
Several more signal molecules stimulating or inhibiting the 
decisions of stem cells await their characterization. Their 
existence is evident from experiments with crude and partial-
ly purified extract. For example, Berking (38) demonstrated 
that hydra crude extract contains an inhibitor which causes 
neuronal precursor cells in S phase to remain precusors and 
prevents them from differentiating to nerve cells. Similarily, 
Fujisawa (39) found in crude extract an endogeneous factor 
preventing precursor cells from differentiating into ste-
noteles. 
Stem cell differentiation in hydra - molecular prospects 
We have reviewed the progress which has been made in the 
last ten years in understanding the differentiation potential of 
interstitial stem cells in hydra. Now a new set of questions is 
raised concerning the molecular mechanisms underlying stem 
cell differentiation. 
(1) What genes are involved in regulation of stem cell 
differentiation? Which cis-acting elements mediate position 
dependent differentiation within the body column? To 
approach these questions, several groups now are identifying 
hydra genes expressed in specific regions and genes expressed 
solely in certain pathways of somatic and germ line dif-
ferentiation. Progress is also being made toward establishing 
a System for manipulating genes in vivo by introducting gene 
constructs into intact polyps via electroporation (Bosch, 
Bode, David and Steele, unpublished results). This will 
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enable identification of D N A sequences Controlling cell type 
specific or region specific gene expression and genes involved 
in proliferation control. In addition, a gene transfer system 
will allow introduction of markers into stem cells and thus 
permit a rigorous in vivo examination of the stem cell lineage 
outlined in Figure 1. 
(2) The neuropeptides H A and RFamide apparently affect 
stem cell behavior. How do they do so? Which cell popula-
tions are the target cells? Which genes are activated? Using 
subtractive hybridization it should be feasible to isolate 
cDNAs for mRNAs made in response to such factor treat-
ment. Equally important for understanding the in vivo func-
tion of these signal molecules will be the characterization of 
the receptors for the particular ligands. Evidence for two 
types of receptors for H A was presented recently by C. 
Schaller's group (40) and it was proposed that different 
functions of the H A molecule are mediated by different 
receptor types. 
(3) «Stem cell Systems in hydra and vertebrates strongly 
suggest the importance of spatial Organization and thus 
extrinsic influences» (41). Can we define these extrinsic 
influences in molecular terms? What components of the 
environment (signal molecules, neuropeptides, growth fac-
tors) are involved in the decision making of stem cells? The 
search for such molecules would clearly be facilitated if signal 
molecules known to play crucial roles in regulation of dif-
ferentiation and development in higher organisms are also 
used in hydra. It is thus encouranging that the first membrane 
associated protein tyrosine kinases and receptors cloned from 
hydra have been found highly homologous to vertebrate 
genes (42, 43, Steele, pers. commun.). 
(4) There is a growing realization of the importance of the 
extracellular matrix in cell differentiation and morphogenesis 
(44). Strong links are emerging between growth factors and 
the ability of cell adhesion molecules and extracellular matrix 
molecules to participate in, and potentially regulate, mor-
phogenesis and differentiation (45). It is tempting to specu-
late, therefore, that in hydra the mesoglea serves as an 
affinity matrix presenting growth and differentiation factors 
along the body axis. By specific release of these factors the 
mesoglea could specify positional information used in the 
spatial regulation of differentiation (46). 
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